|
|
NYVAC vaccine vector |
|
Vaxvec ID |
37 |
|
Vaccine Vector Name |
NYVAC vaccine vector |
|
Vector VO ID |
VO_0001093
|
|
Advantage |
A NYVAC vaccine vector allows for gene expression on a high level and generates antigen-specific immune responses when administered to animals and humans (Perdiguero et al., 2013). |
|
Disadvantage |
A NYVAC vector still contains other viral genes that are immunomodulatory that may repress host immunity, notably genes coding for proteins that antagonize the innate immune response mediated by Toll-like receptor (TLR) signaling. It also remains uncertain that long-term existence of protective immune response will be generated when NYVAC is administered. It has been documented that antibody titers induced by NYVAC for small pox disease were significantly lower than the traditional vaccines. Moreover, NYVAC immunized subjects exhibited qualitative differences in the immune response, resulting in the failure in the induction of antigen-specific antibodies (Perdiguero et al., 2013). |
|
Safety |
NYVAC is a highly attenuated vaccinia strain (Tartaglia et al., 1992). NYVAC is highly regarded as a potential clinical vaccine candidate because it has demonstrated an exemplary safety profile and in vivo efficacy (Perdiguero et al., 2013). |
|
Description |
NYVAC is a vaccinia virus (VACV) strain that is highly attenuated. This vaccine vector possesses limited ability to replicate in human and the majority of mammalian cell types. It has been productively employed to battle emergent infectious diseases and cancer in humans. As a vaccine that has the potential to work against emergent infectious diseases and cancer, NYVAC is undergoing fierce preclinical and clinical testing (Perdiguero et al., 2013). |
| Related Vaccine(s) |
|
| References |
Harari et al., 2012: Harari A, Rozot V, Cavassini M, Bellutti Enders F, Vigano S, Tapia G, Castro E, Burnet S, Lange J, Moog C, Garin D, Costagliola D, Autran B, Pantaleo G, Bart PA. NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. European journal of immunology. 2012; 42(11); 3038-3048. [PubMed: 22930439].
Perdiguero et al., 2013: Perdiguero B, Gómez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, Calandra T, Pantaleo G, Esteban M. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PloS one. 2013; 8(9); e74831. [PubMed: 24069354].
Tartaglia et al., 1992: Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992; 188(1); 217-232. [PubMed: 1566575].
|
|
